nanomedicin
seen
increas
interest
medic
commun
recent
year
enabl
modif
engin
devic
deliveri
interact
cell
environ
particular
technolog
enabl
advanc
design
deliveri
system
drug
vaccin
nanoparticl
np
engin
differ
biodegrad
materi
includ
natur
synthet
polym
poli
lacticcoglycol
acid
plga
polylact
acid
pla
metal
gold
copper
oxid
aluminum
oxid
zinc
oxid
iron
oxid
silver
lipid
phosphatidylserin
phosphatidylcholin
cholesterol
np
microparticl
mp
wide
use
deliv
drug
especi
cytotox
drug
immunesuppress
treatment
transplant
np
effect
distribut
medic
target
specif
organ
control
drug
deliveri
drug
carrier
transport
drug
site
cancer
target
diseas
organ
prevent
damag
healthi
cell
also
protect
drug
degrad
metal
nanoparticl
eg
gold
silver
plga
may
dual
function
work
carrier
target
deliveri
system
use
membran
cancer
cell
contain
tumorassoci
marker
recent
studi
fang
et
al
use
membran
mous
melanoma
cancer
cell
outer
layer
plga
nanoparticl
np
stabl
persist
structur
cellular
endocytosi
activ
matur
dendrit
cell
dc
present
especi
cell
tcr
bind
induc
product
ifng
moreov
author
found
plga
cover
membran
receptor
allow
interact
cancer
cell
deliveri
drug
furthermor
np
use
deliv
drug
specif
site
organ
transplant
prevent
reject
system
immunosuppress
high
risk
recipi
organ
transplant
use
high
dose
immunosuppress
agent
make
suscept
infect
case
caus
death
previou
studi
found
diabet
mice
transplant
islet
eye
prevent
islet
graft
immun
reject
vivo
use
rapamycin
mp
islet
transplant
immunosuppress
drug
mp
surviv
month
compar
control
empti
mp
reject
islet
second
week
work
last
decad
increas
knowledg
infecti
diseas
mechan
evas
immun
respons
howev
new
variant
antibioticresist
pathogen
microorgan
emerg
becom
challeng
design
new
vaccin
adjuv
vaccin
develop
liveattenu
microorgan
kill
pathogen
firstgener
vaccin
dna
vaccin
thirdgener
vaccin
subunit
vaccin
synthet
peptid
secondgener
vaccin
last
three
vaccin
type
elimin
risk
develop
diseas
must
use
conjunct
adequ
adjuv
deliveri
system
tabl
combin
vaccin
adjuv
deliveri
system
safe
stabl
abil
induc
longliv
memori
b
cell
respons
prefer
singl
dose
maximum
two
dose
free
strict
storag
requir
dna
rna
vaccin
safe
need
second
boost
recombin
protein
dna
anoth
vector
np
becom
altern
target
vaccin
deliveri
immun
cell
improv
vaccin
efficaci
slow
releas
easi
antigen
uptak
induct
humor
cellular
respons
np
play
import
role
activ
antigenpres
cell
apc
especi
dc
may
determin
vaccin
efficaci
although
cytotox
effect
np
risk
low
compar
benefit
vaccin
deliveri
chapter
summar
differ
nanocarrierbas
vaccin
formul
achiev
desir
host
immun
infecti
diseas
cancer
end
discuss
limit
respect
carrier
dc
special
apc
coordin
innat
adapt
immun
respons
variou
type
np
compos
gold
dendrim
carbon
polym
liposom
use
deliv
vaccin
stimul
product
cytokin
antibodi
respons
cargo
limit
vaccin
possibl
add
adjuv
immun
stimulatori
molecul
includ
silica
iron
tlr
agonist
cytokin
improv
immunogen
sever
vaccin
test
differ
type
np
tabl
liposom
secondmost
common
type
np
selfassembl
water
special
condit
compos
lipid
hydrophil
head
hydrophob
tail
maintain
hydrophil
inner
outer
membran
lamellar
lipid
bilay
multilay
simul
vesicl
found
within
cell
liposom
induc
cellular
respons
humor
respons
depend
charg
size
lipid
composit
previou
studi
show
charg
main
role
activ
cellular
humor
immun
respons
author
approach
investig
import
antigeneliposom
interact
immunogen
depot
format
use
subunit
antigen
pi
tb
pi
chlamydia
vaccin
model
antigen
lysozym
pi
inject
cation
dimethyldioctadecylammonium
use
np
platform
liposom
emuls
nanogel
substanc
b
nanovaccin
access
lymphat
drainag
system
lymph
node
deliveri
protect
cargo
environment
degrad
lymph
node
nanocarri
deliv
cargo
apc
immun
process
c
nanovaccin
properti
tune
effici
deliv
cargo
maximum
immun
activ
exampl
np
modifi
target
specif
subset
immun
cell
also
deliv
specif
intracellular
compart
receptor
immun
pathway
trigger
migrat
secondari
lymph
node
activ
b
cell
author
analyz
manuscript
previou
studi
shown
dda
induc
proinflammatori
cytokin
chemokin
infiltr
monocyt
macrophag
vivo
one
advantag
liposom
mimick
properti
pathogen
induc
humor
cellular
immun
respons
antigen
present
apc
depend
membran
characterist
size
ligandreceptor
bind
liposom
could
induc
respons
lipid
unsatur
wherea
satur
lipid
promot
immun
respons
liposom
could
modifi
accord
need
deliveri
produc
tfh
immun
respons
cation
liposom
increas
uptak
subunit
vaccin
synthet
peptid
recombin
protein
explain
interact
posit
charg
liposom
apc
neg
charg
membran
anoth
modif
phsensit
fusogen
liposom
stabl
neutral
ph
acid
condit
antigen
releas
present
mhc
class
ii
liposom
contain
phosphatidylethanolamin
amphiphil
stabil
allow
pecontain
liposom
form
aggreg
due
poor
hydrat
headgroup
explain
high
affin
adher
cell
membran
anoth
studi
design
uniqu
structur
compos
interbilayercrosslink
multilamellar
vesicl
icmv
stabl
extracellular
environ
rapidli
releas
endosomeslysosom
therebi
enhanc
vaccin
immun
respons
icmv
carri
antigen
ova
mix
adjuv
monophosphoryl
lipid
mpla
mixtur
amplifi
vaccin
respons
upregul
costimulatori
cell
splenic
bone
marrow
dc
addit
splenic
dc
incub
ova
vaccin
mpla
trigger
prolifer
na
ive
cell
vitro
suggest
icmv
enhanc
crosspresent
antigen
result
obtain
vivo
vaccin
mice
mixtur
icmv
elicit
robust
antibodi
titer
greater
simpl
liposom
result
could
attribut
activ
enhanc
dc
antigen
cross
present
first
use
liposom
deliveri
system
malaria
vaccin
ballou
et
al
synthet
peptid
deriv
repetit
region
circumsporozoit
cs
protein
plasmodium
falciparum
sporozoit
synthet
peptid
conjug
keyhol
limpet
hemocyanin
klh
protein
incorpor
liposom
immun
mice
rabbit
produc
antibodi
repeat
region
protein
biolog
activ
correl
protect
rt
vaccin
malaria
phase
three
clinic
trial
africa
rt
vaccin
central
repeat
region
csp
cell
epitop
local
ctermin
region
fuse
hepat
b
surfac
antigen
hbsag
express
saccharomyc
cerevisia
yeast
viruslik
particl
vlp
vaccin
also
contain
mpla
enhanc
humor
cell
respons
first
year
level
protect
protect
decreas
rapidli
thereaft
neg
efficaci
children
problem
rt
adjuv
system
induc
potent
immun
respons
howev
csp
part
rt
antigen
polymorph
cell
epitop
present
cs
protein
incorpor
vaccin
also
polymorph
address
problem
newest
gener
vaccin
coformul
matrixm
saponinbas
liposom
adjuv
howev
vaccin
protect
p
falciparum
achiev
due
shortliv
memori
cell
evas
mechan
parasit
first
malaria
vaccin
test
anim
use
plasmodium
berghei
radiationattenu
sporozoit
protect
hoffman
et
al
report
human
volunt
vaccin
irradi
sporozoit
p
falciparum
strain
protect
week
vaccin
use
vaccin
children
year
three
african
countri
ghana
malawi
kenya
vaccin
could
prevent
case
accord
previou
clinic
trial
viruslik
particl
vlp
compos
selfassembl
viral
membran
maintain
viral
surfac
protein
vlp
modifi
express
addit
protein
microorgan
could
engin
fusion
protein
membran
antigen
endogen
express
antigen
gardasil
fourcompon
vlptype
vaccin
specif
hpv
contain
major
capsid
protein
hpv
type
administ
along
aluminum
adjuv
vaccin
administ
women
follow
incid
persist
associ
infect
month
efficaci
prevent
clinic
diseas
hpv
combin
vaccin
immunogen
induc
product
longliv
antibodi
howev
problem
vaccin
teenag
girl
report
advers
event
includ
dermatolog
mucosaallerg
reaction
rash
localinjectionsit
reaction
howev
seriou
advers
event
follow
immun
report
report
includ
two
incid
anaphylaxi
two
seizur
one
incid
thrombocytopenia
one
death
inorgan
metal
np
frequent
use
drug
deliveri
bioimag
especi
treat
cancer
patient
dna
vaccin
stabl
protect
degrad
carri
gold
silica
silver
np
deliveri
system
coval
attach
gnp
increas
np
molecular
weight
enhanc
dna
bind
stabil
without
compromis
dna
releas
transfer
hbsag
complex
induc
effect
antibodi
cell
respons
immun
balbc
mice
contrast
nake
dnaprim
hbsag
induc
antibodi
seri
four
immun
mg
nake
dna
hbsagspecif
cell
elimin
target
cell
sensit
hbsag
ctl
epitop
peptid
vitro
chimer
np
employ
minim
amount
dna
induc
effect
immun
respons
compar
nake
dna
biodegrad
polym
signific
interest
deliveri
drug
vaccin
infecti
diseas
polym
consist
either
natur
synthet
monom
biodegrad
nonimmunogen
low
cytotox
easi
prepar
sever
polym
chitosan
plga
polyethylen
glycol
peg
polycaprolacton
dextran
use
deliveri
system
plga
approv
human
use
us
food
drug
administr
fda
european
medicin
agenc
ema
plga
use
deliv
drug
long
period
dc
play
import
role
activ
adapt
immun
respons
b
cell
cell
activ
differenti
subpopul
determin
humor
cellular
immun
respons
elimin
microorgan
cruz
et
al
studi
deliveri
np
mp
dc
creat
biocompat
biodegrad
slowreleas
vaccin
effect
target
cell
np
mp
plgaepeg
load
tetanu
toxoid
peptideefitc
link
lyse
cathepsin
cleavag
site
antidcsign
antibodi
dc
target
plgabas
vaccin
np
mp
np
effici
taken
help
antidcsign
antibodi
induc
prolifer
cell
fig
howev
mp
taken
apc
includ
dc
fig
new
research
need
understand
biolog
antigen
process
present
need
induc
longliv
memori
b
cell
botul
lethal
neuroparalyt
diseas
produc
clostridium
botulinum
toxin
ah
ruwona
et
al
demonstr
cation
plga
np
carri
plasmid
dna
encod
bont
heavychain
hc
fragment
product
nontox
immun
mice
produc
high
titer
antibodi
week
fig
four
immun
specif
decreas
increas
compar
first
immun
challeng
mice
vaccin
plgae
surviv
mice
immun
nake
plasmid
protect
fig
modif
polymer
np
use
deliv
synthet
peptid
recombin
protein
dendrit
cell
macrophag
salvador
et
al
modifi
plga
ms
lactideeglicolid
ratio
produc
cation
np
use
polyethylen
imin
pei
bsa
antigen
addit
np
modifi
encapsul
monophosphoryl
lipid
mpla
polyinosinicpolycytidil
acid
poli
c
agalactosyl
ceramid
address
adjuv
effect
coumarin
incorpor
oili
phase
prepar
fluoresc
np
evalu
vitro
assay
np
test
vitro
use
monocyt
dendrit
cell
mice
immun
differ
np
modif
determin
immun
respons
vivo
cation
np
show
notic
enhanc
uptak
monocyt
mdc
pdc
comparison
classic
np
addit
cation
np
increas
immunostimulatori
effect
sinc
induc
product
antibodi
cell
respons
produc
ifng
interest
compani
nanoparticlebas
vaccin
deliveri
dramat
increas
last
decad
pevion
biotech
ltd
swiss
compani
found
develop
virosomebas
technolog
platform
make
effici
safe
prophylactictherapeut
vaccin
candid
candida
albican
caus
vulvovagin
mucos
infect
pevion
use
aspartylproteinas
immunodomin
antigen
virul
factor
recombin
protein
assembl
virosom
evalu
mous
model
initi
clinic
trial
women
show
candid
vaccin
intravagin
administ
therapeut
potenti
treatment
recurr
candidiasi
addit
compani
test
malaria
vaccin
africa
vaccin
combin
ffm
test
phase
iiia
clinic
trial
although
vaccin
show
steril
protect
induc
respons
blood
stage
parasit
lower
rate
parasit
growth
human
volunt
vaccin
compar
unvaccin
control
glaxosmithklin
plc
work
improv
coformul
rt
vaccin
use
matrixm
saponinbas
liposom
adjuv
novavax
develop
respiratori
syncyti
viru
rsv
f
nanoparticl
vaccin
aluminum
purpos
report
studi
evalu
safeti
efficaci
matern
transfer
antibodi
prevent
rsv
infant
vaccin
healthi
thirdtrimest
pregnant
women
show
signific
protect
newborn
children
rsv
challeng
reduc
pulmonari
inflamm
vaccin
safe
effect
matern
nanoparticlebas
vaccin
opportun
limit
adult
vaccin
furthermor
compani
work
recombin
trival
nanoparticl
influenza
vaccin
matrix
vaccin
induc
respons
one
conserv
ha
head
stem
epitop
antibodi
respons
abl
neutral
homolog
heterolog
strain
nanoparticl
use
recent
year
advanc
clinic
trial
vaccin
rsv
infect
three
studi
use
rsv
f
nanoparticl
vaccin
aluminum
phase
trial
first
clinic
studi
rsv
rsv
f
doserang
studi
women
start
octob
finish
may
studi
show
formul
well
toler
without
treatmentrel
seriou
advers
event
antibodi
antif
igg
palivizumabcompetit
antibodi
respons
correl
increas
dose
microneutr
assay
increas
significantli
first
dose
plateau
second
studi
rsv
f
vaccin
matern
immun
studi
healthi
thirdtrimest
pregnant
women
start
septemb
finish
june
studi
demonstr
vaccin
safe
infant
pregnant
women
third
clinic
studi
phase
three
trial
finish
juli
vaccin
safe
effect
infant
pregnant
women
studi
evalu
safeti
immunogen
recombin
trival
nanoparticl
influenza
vaccin
matrix
adjuv
nanoflu
use
test
protect
peopl
older
age
result
publicli
releas
studi
phase
two
trial
entitl
dose
formul
confirm
quadniv
older
adult
studi
subject
random
seven
treatment
group
receiv
vaccin
activ
compar
tabl
summar
clinic
trial
phase
ieiv
clinic
trialsvaccinesnanoparticl
engin
np
revolution
deliveri
drug
monoclon
antibodi
vaccin
target
cell
np
design
metal
nonmet
polymer
materi
lipid
vlp
bioceram
give
distinct
physicochem
electr
characterist
specif
interact
target
cell
organ
howev
np
enter
easili
human
bodi
cross
lipid
bilay
may
interact
sensit
organ
clearanc
excret
np
mediat
mononuclear
phagocyt
system
renal
urinari
system
biliari
clearanc
macrophag
phagocyt
np
keep
secondari
lymph
organ
andor
liver
use
mertk
mer
receptor
receptor
tyrosin
kinas
famili
axl
respons
promot
apoptot
cell
engulf
support
platelet
aggreg
clot
stabil
vivo
addit
kupffer
cell
liver
macrophag
sequest
nanoparticl
particl
nm
diamet
rapidli
clear
circulatori
system
via
renal
filtrat
hand
studi
shown
metal
np
menp
effect
innat
immun
specif
vitro
assay
show
menp
cytotox
genotox
interfer
cytokin
product
gene
express
due
receptor
modif
respons
innat
immun
system
threat
mediat
inflamm
product
cytokin
chemokin
free
radic
nitric
oxid
reactiv
oxygen
speci
ro
process
accumul
oxid
glutathion
gssg
gener
stress
proinflammatori
signal
involv
tlr
menp
caus
cell
death
cancer
studi
shown
adenoviru
vlp
combin
gene
control
gelsing
ammonia
metabol
encod
ornithin
transcarbamylas
invad
organ
induc
sever
reaction
lead
death
sever
side
reaction
report
carcinogenesi
germlin
alter
observ
anim
model
vlp
becom
wide
dispers
bodi
viral
vector
could
end
ovari
test
eudragit
drug
deliveri
polym
poli
ethyl
acrylatecomethyl
methacrylatecotrimethylammonioethyl
methacryl
chlorid
report
use
macrophag
cocultur
nper
np
close
inner
membran
mitochondria
observ
transmiss
electron
microscopi
author
also
analyz
gene
respons
mitochondri
function
microarray
found
reduc
express
gene
help
maintain
network
morpholog
dynam
regul
signal
pathway
cell
death
nperstreat
cell
reduc
glutathion
gsh
stimul
ro
product
due
unbalanc
oxidanteantioxid
homeostasi
chang
protein
impli
activ
autophagi
mitochondria
decay
phagophor
autophagosom
format
mitophagi
occur
np
character
size
nm
greater
surfac
area
per
mass
compar
largers
particl
chemistri
caus
np
activ
biolog
physicochem
properti
materi
could
increas
uptak
antigenpres
cell
go
tissu
gener
advers
biolog
effect
apoptosi
necrosi
materi
degrad
easili
howev
np
plga
modifi
releas
antigen
slowli
immun
increas
effici
protect
adapt
immun
respons
nevertheless
intranas
immun
np
report
caus
lung
injuri
oxid
stress
induc
product
cytotox
cellular
respons
inflammatori
cytokin
anoth
problem
np
aggreg
may
block
blood
vessel
host
modif
polymer
np
pei
use
prevent
recognit
cell
epitheli
cell
lung
technolog
could
use
singlechain
fragment
region
antibodi
bind
np
recogn
specif
receptor
dendrit
cell
macrophag
may
deliv
antigen
target
organ
modif
np
use
plga
cover
peg
plgaepeg
formul
tetanu
toxoid
peptideefitc
link
lyse
ly
cathepsin
cleavag
site
antidcsign
antibodi
help
deliveri
dc
macrophag
enhanc
effici
prolifer
cell
neg
charg
np
prevent
activ
immun
system
induct
immunotoler
therefor
prevent
effect
exacerb
inflammatori
respons
nanoparticl
also
engin
porou
increas
diffus
intracellular
proteas
result
earlier
process
apc
present
cell
addit
np
carri
antigen
adjuv
np
less
effici
induc
immun
respons
one
adjuv
separ
antigen
differ
np
may
compet
effect
coactiv
sever
pathway
np
wide
explor
vaccin
deliveri
target
apc
especi
dc
despit
advanc
immunolog
critic
understand
mechan
entri
np
cell
activ
adapt
immun
respons
relat
toxic
approach
inhibit
cytokin
chemokin
cascad
dc
b
cell
np
great
potenti
immunolog
although
indepth
studi
toxic
necessari
addit
np
requir
molecul
antibodi
ligand
bind
receptor
target
cell
ensur
np
adher
cell
modif
test
cell
line
anim
prevent
side
effect
death
synthesi
np
shift
method
gener
reproduc
nanoparticl
term
size
nm
allow
elimin
kidney
shape
composit
biodegrad
materi
reduc
cytotox
